跳至主要内容
临床试验/NCT04242706
NCT04242706已完成4 期

VITAL - VAP Prevention in ICU by BACTIGUARD coAting of endotracheaL Tube

Bactiguard AB3 个研究点 分布在 1 个国家目标入组 323 人开始时间: 2018年10月31日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
Bactiguard AB
入组人数
323
试验地点
3
主要终点
VAP incidence

研究概览

简要总结

The study objective is to determine VAP (Ventilator Associated Pneumonia) baseline incidence in the ICU in patients receiving endotracheal tubes with evacuation lumen with and without Bactiguard coating. The study is randomized, prospective, controlled and blinded. All adult patients hospitalized in the ICUs from two tertiary hospitals (i.e.: Centre Hospitalier Universitaire Sart Tilman Liège , Centre Hospitalier Chrétien de Liège) and considered to be ventilated for more than 24 hours will be eligible to participate in the study.

详细描述

The aim of the study is to determine VAP (Ventilator Associated Pneumonia) baseline incidence in the ICU in patients receiving endotracheal tubes with evacuation lumen with and without Bactiguard Infection Protection (BIP) coating.

VAP is likely to occur in 10-20% of patients who are ventilated for at least 48 hours. These patients face a mortality risk estimated to be twice as high compared with similar ICU patients without VAP. Furthermore, VAP results in an average excess length of ICU stay with high hospital cost.

Bactiguard has developed an endotracheal tube coated with a thin layer of non-releasing metals (gold, silver and palladium) firmly attached to the surface. This Bactiguard coating is tissue friendly and aims to achieve an optimal combination of anti-infective properties to reduce biofilm formation, colonization and subsequent respiratory infection. Bactiguard coated urinary products have been on market since 1995 (initially in US, then also in Japan & Europe) and used in a large number of clinical studies and evaluations, showing reduction of urinary tract infections and also antibiotics use. A BIP ETT (without evacuation lumen) clinical safety and tolerability study was performed at Karolinska University Hospital during 20128. The study showed that BIP ETT is safe, well tolerable and performs well in clinical settings.

The present study of BIP ETT with evacuation lumen is randomized, prospective, controlled and blinded. All adult ICU patients hospitalized in the ICUs from two tertiary hospitals (i.e.: Centre Hospitalier Universitaire Sart Tilman Liège , Centre Hospitalier Chrétien de Liège) and considered to be ventilated for more than 24 hours will be eligible to participate in the study. 300 patients in total will be used to determine baselines levels (150 in each group).

The study tubes will be available not only in the ICUs but also in the emergency department, including the emergency vehicles, and in every hospital wards. The study tubes will not be available in the operating rooms except in the Post Anesthesia Care Units (PACU) and Recovery rooms.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

盲法说明

Blinded, the two devices have the same appearance.

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • intubation with a study tube and a presumed duration of ventilation for more than 24h,
  • age > 18 y,
  • signed informed consent

排除标准

  • tracheostomized patient
  • life expectancy less than 48h,
  • previous participation in the study
  • pregnant women.

结局指标

主要结局

VAP incidence

时间窗: Up to 28 days after inclusion

Ventilator Associated Pneumonia incidence

次要结局

  • Antibiotics consumption(Up to 28 days after inclusion)
  • Duration of ventilation(Up to 28 days after inclusion)
  • VAT incidence(Up to 28 days after inclusion)
  • Duration of ICU and hospital stay(Up to 28 days after inclusion)
  • VAC and iVAC(Up to 28 days after inclusion)
  • Nosocomial infections(Up to 28 days after inclusion)
  • Mortality(Up to 60 days after inclusion)
  • Tracheal bacterial colonization(Up to 28 days after inclusion)

研究者

发起方
Bactiguard AB
申办方类型
Industry
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验